Overview

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

Status:
Completed

Trial end date:
2020-05-31

Target enrollment:

Participant gender:

Summary

This study will investigate the PK, relative bioavailability, safety, and tolerability of the extended release (ER) 50 mg MN-166 (ibudilast) tablet formulation as compared to the intermediate-release (IR) capsule formulation of MN-166 (ibudilast) and to examine the effect of food on the pharmacokinetics of the ER formulation.

Phase:

Phase 1

Details

Lead Sponsor:

MediciNova

Treatments:

Ibudilast